iRhythm Holdings Announces Third Quarter 2026 Financial Results

iRhythm posts strong revenue growth but remains GAAP unprofitable amid major portfolio expansion.

What the company is saying

iRhythm Holdings, Inc. is highlighting a 14.9% year-over-year revenue increase to $221.6 million for Q3 2026, with gross margin rising 310 basis points to 74.2%. The company frames its narrative around robust demand for Zio Monitor, operational efficiency, and broad-based momentum across multiple care settings. Management, led by President and CEO Quentin Blackford, emphasizes significant margin expansion and strategic execution, attributing improved results to volume growth and efficiency initiatives. The announcement spotlights the completed acquisition of VitalConnect on October 5, 2026, which immediately adds an FDA-cleared mobile cardiac telemetry device to the portfolio and is expected to contribute $16 million in revenue through year-end. iRhythm also stresses its increased full-year 2026 revenue guidance to $890–$895 million and adjusted EBITDA margin guidance to 15.5%–16.0%. The company references three large-scale real-world studies supporting product superiority but does not provide numerical outcomes. A new $300 million senior secured revolving credit facility is presented as a move to support long-term growth.

What the data suggests

The disclosed figures show iRhythm's Q3 2026 revenue at $221.6 million, up from $192.9 million in Q3 2025, and gross profit rising to $164.5 million from $137.1 million. Gross margin improved to 74.2%. Despite these gains, GAAP net loss widened to $29.9 million from $5.2 million, or $0.90 per diluted share versus $0.16. Adjusted EBITDA improved by $29.6 million to $51.2 million, with margin up 1,190 basis points to 23.1%. Adjusted net income swung to $27.8 million from a $2.0 million loss, or $0.82 per share versus a $0.06 loss. Operating expenses increased to $197.0 million, but adjusted operating expenses fell to $138.6 million. Unrestricted cash, cash equivalents, and marketable securities totaled $560.7 million. The company closed the VitalConnect acquisition and a $300 million revolving credit facility. Full-year guidance was raised, with $16 million of expected VitalConnect revenue included. The financial trajectory is positive on an adjusted basis, but the company remains GAAP unprofitable. Claims of product superiority in clinical studies are not substantiated with numerical data in this release.

Analysis

The announcement is generally positive in tone, highlighting strong revenue growth, margin expansion, and a swing to adjusted net income. These improvements are supported by detailed numerical disclosures, including both GAAP and adjusted profitability metrics. However, the company remains GAAP unprofitable, with the net loss widening year-over-year, which tempers the overall signal. The acquisition of VitalConnect and the new $300 million credit facility represent significant capital moves, but the benefits from these actions are only partially realised and much of the expected impact is embedded in forward-looking guidance for the remainder of 2026. Claims of product superiority from published studies are not substantiated with numerical outcomes in this release, inflating the narrative relative to the evidence. The forward-looking ratio is moderate, with most key claims realised but some future projections and qualitative statements about ongoing momentum and innovation. Overall, the narrative is somewhat inflated by promotional language and unquantified claims, but the core financial progress is real and measurable.

Risk flags

• ●GAAP net loss increased to $29.9 million in Q3 2026 from $5.2 million in Q3 2025, indicating that despite strong top-line and adjusted profitability, the company is not yet generating GAAP profits. This persistent unprofitability exposes iRhythm to ongoing capital needs and market scrutiny.
• ●The acquisition of VitalConnect introduces integration risk, as the company must successfully combine operations, realize anticipated synergies, and deliver the forecasted $16 million in incremental revenue within a short timeframe. Failure to integrate or achieve expected benefits could undermine guidance.
• ●The new $300 million senior secured revolving credit facility increases financial leverage. If revenue growth or margin expansion falters, higher debt levels could pressure liquidity and financial flexibility.
• ●Product superiority claims from three large-scale studies are not supported by disclosed numerical outcomes in this announcement. This lack of quantitative evidence limits the ability of investors to independently assess the clinical and commercial impact of these findings.
• ●Raised guidance for revenue and adjusted EBITDA margin depends on continued volume growth and operational execution. Any slowdown in demand, reimbursement changes, or operational setbacks could cause the company to miss these targets.

Bottom line

iRhythm delivered strong revenue and margin growth in Q3 2026, but remains GAAP unprofitable with net loss widening year-over-year. The VitalConnect acquisition and new credit facility signal aggressive portfolio and liquidity expansion, with $16 million in expected near-term revenue from the acquired business. Adjusted EBITDA and net income metrics show operational improvement, but the absence of GAAP profitability and reliance on adjusted figures warrant caution. Claims of clinical superiority are not backed by data in this release, limiting independent validation of product differentiation. Investors should focus on the company's ability to integrate VitalConnect, deliver on raised guidance, and move toward sustained GAAP profitability. The most important takeaway is that while operational momentum is real, the investment case hinges on execution and the transition from adjusted to GAAP profitability.

Announcement summary

(NASDAQ:IRTC) iRhythm Holdings, Inc. reported financial results for the third quarter ended September 30, 2026. Revenue for the third quarter of 2026 was $221.6 million, representing a 14.9% increase compared to $192.9 million in the third quarter of 2025. Gross profit for the quarter was $164.5 million, up from $137.1 million in the prior year period, with a gross margin of 74.2%, a 310-basis point improvement. The company reported a GAAP net loss of $29.9 million, or $0.90 per diluted share, compared to a GAAP net loss of $5.2 million, or $0.16 per diluted share, in the third quarter of 2025. Adjusted EBITDA for the quarter was $51.2 million, with an adjusted EBITDA margin of 23.1%, representing a $29.6 million and 1,190-basis point improvement, respectively, over the prior year period. Adjusted net income for the third quarter of 2026 was $27.8 million, or $0.82 per diluted share, compared to an adjusted net loss of $2.0 million, or $0.06 per diluted share, in the third quarter of 2025. Operating expenses for the quarter were $197.0 million, compared to $145.6 million in the prior year, while adjusted operating expenses were $138.6 million, down from $141.4 million. Unrestricted cash, cash equivalents, and marketable securities totaled $560.7 million as of September 30, 2026. The company completed the acquisition of VitalConnect on October 5, 2026, broadening its cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac telemetry offering. iRhythm published three large-scale real world studies demonstrating product superiority of Zio AT (CAMELOT-ALERT 1), Zio Long-Term Continuous Monitoring (EXCALIBUR 2), and improvements in Zio Monitor performance and diagnostic yield compared with Zio XT 3 in over 1.7 million total patients. The company submitted FDA 510(k) applications for pediatric use with its Zio Monitor long-term continuous monitoring business. On November 3, 2026, iRhythm closed a new $300 million senior secured revolving credit facility. For the full year 2026, iRhythm increased its revenue guidance to a range of $890 million to $895 million, including approximately $16 million of expected VitalConnect revenue contribution from the acquisition close through year-end. Adjusted EBITDA margin guidance for 2026 was raised to 15.5% to 16.0%, inclusive of VitalConnect. The company attributes its financial performance to healthy volume-led revenue growth of Zio Monitor, robust margin expansion, and broad-based momentum across cardiology, primary care, innovative channels, and international markets. Quentin Blackford, President and Chief Executive Officer of iRhythm, stated that demand for Zio Monitor exceeded expectations and highlighted the company's focus on advancing innovation, expanding access, and investing in growth initiatives. The company’s total assets as of September 30, 2026, were $1,091,441,000, with total liabilities of $914,335,000 and total stockholders’ equity of $177,106,000. Accounts receivable, net, were $81,126,000, and inventory was $23,222,000 as of September 30, 2026. Accounts payable were $15,395,000, and accrued liabilities were $167,630,000. Long-term senior convertible notes totaled $651,858,000. The company had 33,414 shares issued and 33,185 shares outstanding as of September 30, 2026. The company’s guidance reflects continued volume-led growth and operating leverage while maintaining disciplined investment in innovation and market expansion.

Disagree with this article?